Effects of pranidipine, a novel calcium channel antagonist, on the progression of left ventricular dysfunction and remodeling in rats with heart failure

Pharmacology

Volumn 72, Issue 1, 2004, Pages 26-32

  Ibne Wahed, Mir Imam ^a   Watanabe, Kenichi ^a   Ma, Meilei ^a   Nakazawa, Mikio ^b   Takahashi, Toshihiro ^b   Hasegawa, Go ^b   Naito, Makoto ^b   Yamamoto, Tadashi ^b   Kodama, Makoto ^b   Aizawa, Yushifusa ^b  

^a NIIGATA UNIVERSITY OF PHARMACY AND APPLIED LIFE SCIENCES   (Japan)

^b NIIGATA UNIVERSITY   (Japan)

Author keywords

Calcium channel antagonists; Fibrosis; Heart failure; Pranidipine; Remodeling; TGF 1

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; COLLAGEN TYPE 3; DRUG VEHICLE; MESSENGER RNA; PRANIDIPINE; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; BODY WEIGHT; CENTRAL VENOUS PRESSURE; CONTROLLED STUDY; DIASTOLE; DISEASE COURSE; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; DRUG SCREENING; HEART FAILURE; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART VENTRICLE REMODELING; HEART WEIGHT; IMMUNIZATION; LOW DRUG DOSE; MALE; MYOCARDITIS; NONHUMAN; PRIORITY JOURNAL; RAT; SURVIVAL; SURVIVAL RATE; SYSTOLE;

ANIMALS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DIHYDROPYRIDINES; HEART FAILURE, CONGESTIVE; HEART RATE; MALE; MYOCARDITIS; RATS; RATS, INBRED LEW; TRANSFORMING GROWTH FACTOR BETA; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 4043132405     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000078629     Document Type: Article

References (39)

1. Taliercio CP, Seward JB, Driscoll DJ, Fisher LD, Gersh BJ, Tajik AJ: Idiopathic dilated cardiomyopathy in the young: Clinical profile and natural history. J Am Coll Cardiol 1985;6:1126-1131.
2. Roberts WC, Siegel RJ, McManus BM: Idiopathic dilated cardiomyopathy: Analysis of 152 necropsy patients. Am J Cardiol 1987;60:1340-1355.
3. Dec GW, Palacios IF, Fallon JT, Aretz HT, Mills J, Lee DCS, Johnson RA: Acute myocarditis in the spectrum of acute dilated cardiomyopathies: Clinical features, histologic correlates, and clinical outcome. N Engl J Med 1985;312:885-890.
4. Matsumori A, Kawai C: An animal model of congestive (dilated) cardiomyopathy: Dilatation and hypertrophy of the heart in the chronic stage in DBA/2 mice with myocarditis caused by encephalomyocarditis virus. Circulation 1982;66:355-360.
5. Klingel K, Hohnenadl C, Canu A, Albrecht M, Seeman M, Mall G, Kandolf R: Ongoing enterovirus-induced myocarditis is associated with persistent heart muscle infection: Quantitative analysis of virus replication, tissue damage and inflammation. Proc Natl Acad Sci USA 1992;89:314-318.
6. Davidoff R, Palacios I, Southern J, Fallon JT, Newell J, Dec GW: Giant cell versus lymphocytic myocarditis: A comparison of their clinical features and long-term outcomes. Circulation 1991;83:953-961.
7. Kodama M, Matsumoto Y, Fujiwara Y, Masani F, Izumi T, Shibata A: A novel experimental model of giant cell myocarditis induced in rats by immunization with cardiac myosin fraction. Clin Immunol Immunopathol 1990;57:250-262.
8. Kodama M, Hanawa H, Saeki M, Hosono H, Inomata T, Suzuki K, Shibata A: Rat dilated cardiomyopathy after autoimmune giant cell myocarditis. Circ Res 1994;75:278-284.
9. Watanabe K, Ohta Y, Nakazawa M, Higuchi H, Hasegawa G, Naito M, Fuse K, Ito M, Hirono S, Tanabe N, Hanawa H, Kato K, Kodama M, Aizawa Y: Lowdose carvedilol inhibits progression of heart failure in rats with dilated cardiomyopathy. Br J Pharmacol 2000;130:1489-1495.
10. Kloner RA, Przyklenk K: Progress in cardioprotection: The role of calcium antagonists. Am J Cardiol 1990;66:H2-H9.
11. Triggle DJ: Calcium antagonists; in Antonaccio M (ed): Cardiovascular Pharmacology. New York, Raven Press, 1990, pp 107-160.
12. Kloner RA, Braunwald E: Effects of calcium antagonists on infarcting myocardium. Am J Cardiol 1987;59:B84-B98.
13. Tatani A, Kunze Dl, Brown AM: Effects of dihydropyridine calcium channel modulators on cardiac sodium channels. Am J Physiol 1988;254:H140-H147.
14. Henry PD: Antiperoxidative actions of calcium antagonists and atherogenesis. J Cardiovasc Pharmacol 1991;18(suppl 1):6-10.
15. Elkayam U, Amin J, Mehra A, Vasquez J, Weber L, Rahimtoola SH: A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation 1990;82:1954-1961.
16. Barjon JN, Rouleau JL, Bichet D, Juneau C, De Champlain J: Chronic renal and neurohumoral effects of the calcium entry blocker nisoldipine in patients with congestive heart failure. J Am Coll Cardiol 1987;9:622-630.
17. Goldstein RE, Boccuzzi SJ, Cruess D, Nattel S: Adverse Experience Committee, Multicenter Diltiazem Postinfarction Research Group. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. Circulation 1991;83:52-60.
18. Nakayama N, Ikezono K, Mori T, Yamashita S, Nakayama S, Tanaka Y, Hosokawa T, Minami Y, Masutani K, Yamamura Y, Yabuuchi Y: Antihypertensive activity of OPC-13340, a new potent and long-acting dihydropyridine calcium antagonist, in rats. J Cardiovasc Pharmacol 1990;15:836-844.
19. Mori T, Nakayama N, Ohura M, Ikezeno K, Kinoshita S, Kamata M, Hosokawa T, Yamashita S, Yabuuchi Y: Cardiovascular effects of OPC-13340, a potent, long-acting 1,4-dihydropyridine calcium channel blocker, in dogs. Arch Int Pharmacodyn Ther 1993;321:41-56.
20. 2+ channel antagonist, in rats: Comparison with nifedipine and amlodipine. Eur J Pharmacol 1997;324:201-204.
21. Nakayama N, Ikezono K, Ohura M, Yabuuchi Y: Effect of the new long-acting dihydropyridine calcium antagonist pranidipine on the endothelium-dependent relaxation in isolated rat aorta in vitro. Arzneimittelforschung 1993;43:1266-1270.
22. Mori T, Takeuchi T, Ohura M, Miyakoda G, Fujiki H, Orito K, Yoshida K, Hirano T, Yamamura Y, Sumida T, Nakaya Y, Sarake H, Hata F: Pranidipine, a new 1,4-dihydropyridine calcium channel blocker, enhances cyclic GMP-independent nitric oxide-induced relaxation of the rat aorta. Mol Cell Biochem 1998;178:335-343.
23. Takeuchi K, Omura T, Yoshiyama M, Yoshida K, Otsuka R, Shimada Y, Ujino K, Yoshikawa J: Long-acting calcium channel antagonists pranidipine prevents ventricular remodeling after myocardial infarction in rats. Heart Vessels 1999;14:111-119.
24. Kim CS, Matsumori A, Goldberg L, Doye AA, McCoy Q, Gwathmey JK: Effects of pranidipine, a calcium channel antagonist, in an avian model of heart failure. Cardiovasc Drugs Ther 1999;13:455-463.
25. Uehara Y, Kawabata Y, Ohshima N, Hirawa N, Takada S, Numabe A, Nagata T, Goto A, Yagi S, Omata M: New dihydropyridine calcium channel antagonist, pranidipine, attenuates hypertensive renal injury in Dahl salt-sensitive rats. J Cardiovasc Pharmacol 1994;23:970-979.
26. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidium-isothiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-159.
27. Ohta Y, Watanabe K, Nakazawa M, Yamamoto T, Ma M, Fuse K, Ito M, Hirono S, Tanabe N, Hanawa H, Kato K, Kodama M, Aizawa Y: Carvedilol enhances atrial and brain natriuretic peptide mRNA expression and release in rat heart. J Cardiovasc Pharmacol 2000;36(suppl 2):19-23.
28. Packer M, Kessler PD, Lee WH: Calcium channel blockade in the management of severe chronic congestive heart failure: A bridge too far. Circulation 1987;75(suppl V): 56-64.
29. Taira N: Differences in cardiovascular profile among calcium antagonists. Am J Cardiol 1987;59:B24-B29.
30. Janero DR, Burghardt B: Antiperoxidative effects of dihydropyridine calcium antagonists. Biochem Pharmacol 1999;38:4344-4348.
31. Szabo C, Thiemermann C, Vane JP: Dihydropyridine antagonists and agonists of calcium channels inhibit the induction of nitric oxide synthase by endotoxin in cultured macrophages. Biochem Biophys Res Commun 1993;196:825-830.
32. Mahe Y, Wakasugi H, Scamps C, Chousaib S, Tursz T: Role of calcium on interleukin-1 production by monocytes: Its relevance during T-cell proliferation. Lymphokine Cytokine Res 1991;10:165-172.
33. Yuan Z, Kishimoto C, Shioji K: Beneficial effects of benedipine in acute autoimmune myocarditis: Suppressive effects on inflammatory cytokines and inducible nitric oxide synthase. Circ J 2003;67:545-550.
34. Yang J, Fukuo K, Morimoto S, Niinobu T, Suhara T, Ogihara T: Pranidipine enhances the action of nitric oxide released from endothelial cells. Hypertension 2000;35:82-85.
35. Katz AM: Cardiomyopathy of overload: A major determinant of prognosis in congestive heart failure. N Engl J Med 1990;322:100-110.
36. Morgan JP, Erny RE, Allen PD, Grossman W, Gwathmey JK: Abnormal intracellular calcium handling, a major cause of systolic and diastolic dysfunction in ventricular myocardium from patients with heart failure. Circulation 1990;81(suppl III):21-32.
37. Bristow MR, Hershberger RE, Port DJ, Gilbert EM, Sandoval A, Rasmussen R, Cates AE, Feldman AM: β-Adrenergic pathways in non-failing and failing human ventricular myocardium. Circulation 1990;82(suppl I):12-25.
38. Boluyt MO, O'Neill L, Meredith AL, et al: Alterations in cardiac gene expression during the genes encoding extracellular matrix components. Circ Res 1994;75:22-32.
39. Weber KT, Sun Y, Tyagi SC, Cleutjens JP: Collagen network of the myocardium: function, structural remodeling and regulatory mechanisms. J Mol Cell Cardiol 1994;26:279.